Ovarian cancer, version 1.2019 featured updates to the nccn guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee May Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Charles A. Leath, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHaleKaren McLean, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, Anita M. Engh

Research output: Contribution to journalReview articlepeer-review

67 Scopus citations

Abstract

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years fromdiagnosis. Amajor challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.

Original languageEnglish (US)
Pages (from-to)896-909
Number of pages14
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number8
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Ovarian cancer, version 1.2019 featured updates to the nccn guidelines'. Together they form a unique fingerprint.

Cite this